Discover

NBY
NovaBay Pharmaceuticals Inc
1.95
300 x undefined
200 x undefined
bid
ask
+
0.36
22.64%
250 @ 04:00 PM
1.98 +0.03 (1.54%)
Ytd-93.09%
1y-30.11%
1.57
day range
1.98
0.36
52 week range
9.10
Open1.58Prev Close1.59Low1.57High1.98Mkt Cap2.52M
Vol626.37KAvg Vol476.87KEPS-74.61P/EN/AForward P/E-0.63
Beta0.73Short Ratio0.07Inst. Own2.58%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1250-d Avg0.63200-d Avg1.851yr Est3.73
Earning
DateForEstimateReportedSurprisesurprise %
2025-11-072025-090N/A-0.02-9.52%
2025-08-142025-060N/A-0.13-61.90%
2025-05-152025-030N/A-0.37-154.17%
2025-04-012024-120N/AN/AN/A
2024-11-072024-090N/A-0.32-114.29%
2024-08-132024-060N/AN/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-11-11Ascendiant CapitalUpgradeBuyBuy
2023-08-11Ladenburg ThalmannUpgradeBuyBuy
Profile
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Insider Holder
DateNameRelationQuantityDescription
2023-05-10FREIMAN PAUL EDWARDDirector1.78KConversion of Exercise of derivative security
2023-05-10GARLIKOV JULIEDirector858.00Conversion of Exercise of derivative security
2023-05-10SIT SWANDirector1.72KConversion of Exercise of derivative security
2023-05-10WU MIJIADirector1.72KConversion of Exercise of derivative security
2023-05-10ZHENG JEFF YENYOUDirector1.72KConversion of Exercise of derivative security
2023-05-10ZHENG YONGXIANGDirector858.00Conversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29C2c Wealth Management, LLC 42.95K22.19K0.88%
2024-09-29Geode Capital Management, LLC26.34K13.61K0.54%
2024-09-29UBS Group AG21.06K10.88K0.43%
2024-09-29Virtu Financial LLC19.59K10.12K0.40%
2024-09-29Warberg Asset Management LLC10.00K5.17K0.20%
2024-09-29Tower Research Capital LLC (TRC)5.48K2.83K0.11%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-10-30Fidelity Extended Market Index Fund25.85K13.36K0.53%
2024-10-30Fidelity Series Total Market Index Fund7.35K3.80K0.15%
2024-09-29Vanguard Extended Market Index Fund392.00202.000.01%
2024-09-29Blackstone Alternative Multi-Strategy Fund31.0016.000.00%
Dividend
DividendDate
0.82025-09-30
Split
SplitDate
1 : 52026-02-23
1 : 352024-05-31
1 : 352022-11-16
1 : 252015-12-21
1 : 252015-12-18